Related Experiment Video
Updated: May 17, 2026

Intrastriatal Injection of Autologous Blood or Clostridial Collagenase as Murine Models of Intracerebral Hemorrhage
Published on: July 3, 2014
Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage
J H Tapia-Pérez1, R Rupa, R Zilke
1Klinik für Neurochirurgie, Otto-von-Guericke Universität, Leipziger Strasse 44, 39120 Magdeburg, Germany. jorge.tapia@med.ovgu.de
Insights
Continuing statin therapy after spontaneous intracerebral hemorrhage (ICH) showed reduced mortality and improved neurological outcomes. This neuroprotective effect may be linked to statins' immunomodulatory properties.
Area of Science:
- Neurology
- Pharmacology
- Cardiology
Background:
- Spontaneous intracerebral hemorrhage (ICH) is a severe neurological event with high mortality.
- Statins, primarily cholesterol-lowering drugs, possess potential neuroprotective and anti-inflammatory properties.
- The impact of continued statin use following acute ICH requires further investigation.
Purpose of the Study:
- To evaluate the association between continued statin use and outcomes in patients with acute intracerebral hemorrhage.
- To assess the effect of statins on mortality, neurological status, and inflammatory markers post-ICH.
Main Methods:
- Retrospective cohort study of 178 patients with acute ICH.
- Comparison of outcomes between 29 patients with continued statin use and 149 non-users.
- Outcomes included inpatient mortality, NIHSS, GOS, and mortality at 10 days, 3 months, and 6 months.
- Analysis of C-reactive protein (CRP), white blood cell (WBC) counts, and hepatic enzymes.
Main Results:
- No mortality was observed in the statin group versus 12.7% in the non-user group by discharge (p=0.04).
- Statin use was associated with significantly lower 6-month mortality (OR=0.32, p=0.04) and a trend towards NIHSS reduction.
- Changes in WBC counts and CRP levels were associated with statin use, suggesting an immunomodulatory effect.
Conclusions:
- Continued statin therapy after acute ICH may be associated with improved neurological function and reduced 6-month mortality.
- The immunomodulatory effects of statins might contribute to their neuroprotective role in ICH.
- Further prospective studies are warranted to confirm these findings.
Abstract:
Spontaneous intracerebral hemorrhage (ICH) often represents a devastating event despite maximal therapeutic efforts. Statins are drugs primarily used as cholesterol reducers with several pleiotropic effects that may result in neuroprotection. In this study, we assessed the continued use of statins after acute ICH. From January 2008 to October 2010, we analyzed a retrospective cohort of 178 patients with acute ICH. Patients with head injury, cerebral tumors, hemorrhage after ischemic stroke, and having a National Institute Health Stroke Scale (NIHSS) score of greater than 30 points on admission were excluded. In 29 patients, statins were continued within the first 24 h after onset of ICH and, subsequently, given daily until discharge, whereas 149 nonusers were used as controls. Inpatient mortality, NIHSS, and Glasgow Outcome Score (GOS) at discharge as well as mortality after 10 days, 3 months, and 6 months were recorded as outcomes. Additionally, changes of C-reactive protein (CRP) and white blood cell (WBC) counts, as well as aspartate transaminase and alanine transaminase levels were assessed. Except for the number of hypertensive and diabetic patients, characteristics on admission were similar between both groups. No mortality was observed in statin users, whereas 19 controls (12.7 %) died (p = 0.04) until discharge; after 10 days, 3 months, and 6 months, a similar trend was found. After 6 months, statin use was associated to lower mortality in regression models (OR = 0.32, 95 % CI = 0.11-0.95, p = 0.04). In the same way, statin use was related to NIHSS reduction (-3.53, 95 % CI = -7.59 to 0.42, p = 0.07). In mixed models, changes of WBC counts and CRP levels were associated with statin use. The hepatic enzymes were similar between groups. The continued use of statins after ICH could be associated to early neurological improvement and may reduce mortality within 6 months. Immunomodulation as a pleiotropic effect of statins may represent one of the underlying mechanisms.
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Ischemic Stroke l: Introduction
Venous Thrombosis III: Interprofessional Care
